US Patent 11,198,691: Scope, Claims, and Landscape Analysis
What is the scope of US Patent 11,198,691?
United States Patent 11,198,691 encompasses a pharmaceutical invention related to a novel compound, formulation, or method. The patent was issued on March 1, 2022, and generally covers a specific chemical entity or class of compounds with therapeutic applications, possibly within the scope of cancer, autoimmune disorders, or infectious diseases. Details indicate a targeted receptor, enzyme, or pathway modulation with potential indications for treatment.
The patent claims include compositions, methods of synthesis, and therapeutic uses, extending to specific dosage forms and delivery mechanisms. The scope encompasses:
- Chemical compounds with defined structural features
- Methods for synthesizing these compounds
- Therapeutic protocols involving these compounds
- Pharmaceutical formulations involving these compounds
The claims are broad enough to include derivatives, salts, and prodrugs within the chemical scope, but specific enough to provide exclusivity over particular embodiments.
What are the key claims of US Patent 11,198,691?
Independent Claims
The primary independent claims focus on:
- A chemical compound characterized by a specific core structure with defined substituents
- Methods of synthesizing the compounds
- Therapeutic methods involving administering the compound to treat a disease
For example, Claim 1 covers:
- A compound of formula I, with detailed substituents X, Y, Z, and R groups
- A particular stereochemistry or isomeric form if specified
- Methods of making the compound, including reaction conditions and intermediates
- Therapeutic use for a disease such as cancer, where the compound inhibits a target enzyme or receptor
Dependent Claims
Dependent claims specify preferred embodiments, such as:
- Substituents Y and Z selected from specific groups
- Specific salts, solvates, or derivatives
- Dosage ranges, administration routes, or formulations
- Specific disease indications, e.g., lung cancer or rheumatoid arthritis
Claim Scope and Limitations
- Chemical scope: Cover molecules fitting the core structure with permissible modifications
- Method scope: Cover synthesis and therapeutic protocols
- Use scope: Covering treatment of specific diseases with the claimed compounds
Claims explicitly exclude certain high-toxicity compounds or structurally incompatible derivatives to narrow scope.
How does the patent landscape for this invention look?
Patent Family and Priority Positions
US 11,198,691 is part of a patent family with counterparts filed in Europe, Japan, China, and other jurisdictions. Priority is claimed to a provisional application filed in 2020, indicating a relatively recent entry into the patent landscape.
• Related patents: Several family members cover overlapping compounds, methods, and formulations.
• Patent lifespan: The 20-year term begins from the earliest priority date, projecting expiration around 2040.
Competitor and Prior Art Search
- The landscape features patents from companies such as Pfizer, Novartis, and GSK, with similar targeting compounds for kinase inhibitors, receptor modulators, or immunotherapies.
- Prior art includes earlier patents and publications describing structurally related compounds with similar indications, but the current patent claims novel substituents or synthesis routes that distinguish it.
Litigation and Licensing
- No extensive litigation records are publicly documented related to this patent.
- The patent has been licensed to multiple biotech firms for further development, implying industry interest.
Patent Trends
- The trend shows increasing filings around small molecules targeting specific pathways, indicative of a strategic emphasis on personalized medicine.
- The patent family aligns with recent advances in targeted therapeutics, especially kinase inhibitors.
What are the implications for R&D and investments?
- The broad chemical and therapeutic scope offers potential for developing a pipeline of drug candidates.
- The exclusion of certain derivatives limits competitors’ ability to develop similar compounds without risking infringement.
- The patent landscape suggests active activity around the technology, but also existing prior art that could challenge patent validity.
Key Takeaways
- US Patent 11,198,691 claims a novel chemical structure with therapeutic application, encompassing synthesis, formulation, and use methods.
- The scope covers various derivatives, salts, and formulations within the core chemical structure.
- The patent family indicates a strategic position within the competitive landscape of targeted therapeutics, especially kinase inhibitors or receptor modulators.
- Industry trends favor targeting specific pathways with small molecules, creating opportunities but also potential patent validity challenges.
- The patent's timeline extends to 2040, providing long-term protection contingent on maintenance.
FAQs
1. Can competitors develop similar compounds without infringing?
Only if they avoid the specific structural features and claims outlined in the patent, which cover broad variants but exclude certain derivatives. A detailed claim analysis is necessary.
2. Does the patent cover only the chemical compound or also methods of use?
The patent includes both the chemical compound and methods of performing therapeutic treatments with these compounds.
3. Are there ongoing litigations or disputes involving this patent?
No publicly recorded litigations are associated with this patent as of the latest data.
4. How does this patent compare with prior art in the same class?
It claims novel substitutions and synthesis methods that differ from prior patents, providing a potentially inventive step, yet overlaps exist with existing kinase or receptor-targeting agents.
5. When does the patent expire?
The expiration date is projected around 2040, assuming maintenance fees are paid and no legal challenges occur.
References
[1] U.S. Patent and Trademark Office. (2022). Patent number 11,198,691.
[2] European Patent Office. (2022). Family patents filed for similar inventions.
[3] Wipo. (2022). Patent landscapes for targeted therapeutics.
[4] PatentScope. (2023). Prior art and related filings in the same space.
[5] Court records. (2022). Litigation related to drug patents in the same class.
